The latest health and pharmaceuticals industry and company news and analysis from FriedlNews
Page 1/9

Austrian Health and Pharma Headlines

Valneva Biotech to Book first Revenues from Flu Vaccine

French-Austrian vaccine maker Valneva booked the first revenues from its flu vaccine, Valneva said. British pharmacy group GlaxoSmithKline delivered the first time the vaccines produced on Valneva's EB66 cell line. The licence payments for the E66-based vaccine will start this year.

June 13, 2016

Valneva Share Nosedived after Announcement about Clinical Studies into New Vaccine

Following the publication of the unsatisfactory outcome of clinical studies of a new vaccine, Valneva saw its share price cave in over 20 percent the morning after. The pharmaceutical company is listed on Vienna Stock Exchange and its share price plummeted to about EUR 2.60 (USD 2.914) at 9.15.

June 6, 2016

Biogena Wants to Expand Globally

Biogena, producer of supplements with headquarters in the City of Salzburg wants to expand. In the coming months up to 20 shops will be opened in big German cities. Moreover, the company wants to launch distribution in France, the owner of the company, Albert Schmidbauer, announced during the opening of the new company headquarters in Salzburg.

May 13, 2016

Boehringer Ingelheim Pharma Austrian Unit Ups 2015 Revenues

German pharma group Boehringer Ingelheim raised revenues by 5.5 percent to EUR 760.2 million (USD 861.5 million) in Austria as well as over 30 countries supervised from Vienna in 2015, the company said. Operating performance grew by 2.4 percent y/y to EUR 1.14 billion.

April 20, 2016

Uniqa Insurance's Private Hospital Investment Investigated by Supreme Court

Listed insurance group Uniqa saw the Austrian supreme court OGH look into the planned acquisition of 75 percent in Vienna-based private hospital Goldenes Kreuz, Uniqa's unit PremiQaMed's Barbara Werwendt told APA, confirming earlier information from the medical chamber.

April 5, 2016

Sanochemia Founder Moves to Supervisory Board

During the shareholder meeting of listed pharmaceutical company Sanochemia Pharmazeutika AG on March 16 the shareholders approved the change of function of company founder Werner Frantsits, who transfers from the CEO chair to supervisory board member seat, the company announced. Felix Epper is another new member of the supervisory board.

March 21, 2016

Valneva Records Impressive Revenue Hike

Valneva, the pharmaceutical group created after the merger of Austria’s Intercell and French firm Lyon double-listed in Paris and Vienna, recorded EUR 83.3 million (USD 93.9 million) in revenue last year, up from EUR 42.4 million in 2014. However, the company posted an only slightly reduced loss of EUR 20.6 million (2014: EUR 26.3 million), CEO Thomas Lingelbach says. He stresses the firm is on the right track to become an integrated vaccine-focused pharma business.

March 21, 2016

Life Sciences Field is Booming in Vienna

Nine percent revenue growth, five percent increase in the workforce and a large increase in business startups - Vienna as a location for life science businesses is attracting companies at a rate never seen before.

October 14, 2015

Antibiotics Company Nabriva Therapeutics Collects USD 120 Mln from Investors

Viennese biotech firm Nabriva Therapeutics, specialized in antibiotics against resistant bacteria, has collected USD 120 million from investors. The financing process took two tranches, law firm Wolf Theiss, which advised investors together with US firm Cooley, announced on Wednesday.

April 9, 2015

Vamed to Manage First Hospital in China

Vamed is about to establish and manage its first hospital in China - in the provincial capital Haikou on the island of Hainan.

March 30, 2015